Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpesvirus 1, Human | 26 | 2016 | 64 | 2.950 |
Why?
|
| Keratitis, Herpetic | 15 | 2016 | 18 | 2.240 |
Why?
|
| Apolipoproteins E | 8 | 2016 | 136 | 2.230 |
Why?
|
| Virus Latency | 16 | 2012 | 49 | 1.520 |
Why?
|
| Peptide Fragments | 5 | 2016 | 301 | 1.300 |
Why?
|
| Antiviral Agents | 8 | 2016 | 189 | 1.000 |
Why?
|
| Diabetic Retinopathy | 2 | 2016 | 77 | 0.910 |
Why?
|
| Virus Activation | 11 | 2012 | 38 | 0.740 |
Why?
|
| Retina | 2 | 2016 | 288 | 0.730 |
Why?
|
| DNA, Viral | 9 | 2012 | 323 | 0.690 |
Why?
|
| Herpes Simplex | 4 | 2012 | 19 | 0.610 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2016 | 126 | 0.550 |
Why?
|
| Rabbits | 17 | 2013 | 292 | 0.510 |
Why?
|
| Retinal Neovascularization | 1 | 2016 | 10 | 0.500 |
Why?
|
| Disease Models, Animal | 14 | 2016 | 1554 | 0.500 |
Why?
|
| Stephania | 1 | 2016 | 1 | 0.490 |
Why?
|
| Leucine | 1 | 2016 | 30 | 0.490 |
Why?
|
| Fructose | 1 | 2016 | 23 | 0.490 |
Why?
|
| Receptors, LDL | 1 | 2016 | 40 | 0.490 |
Why?
|
| Eye | 3 | 2016 | 80 | 0.490 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 62 | 0.480 |
Why?
|
| Analgesics | 1 | 2016 | 55 | 0.470 |
Why?
|
| Trigeminal Ganglion | 8 | 2011 | 13 | 0.460 |
Why?
|
| Animals | 33 | 2019 | 16694 | 0.450 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 222 | 0.430 |
Why?
|
| Mice, Inbred C57BL | 7 | 2018 | 1804 | 0.420 |
Why?
|
| Endothelial Cells | 2 | 2018 | 324 | 0.420 |
Why?
|
| Mice | 15 | 2018 | 6490 | 0.410 |
Why?
|
| Pain | 1 | 2016 | 283 | 0.390 |
Why?
|
| Virus Shedding | 1 | 2012 | 9 | 0.390 |
Why?
|
| Plant Extracts | 1 | 2016 | 303 | 0.390 |
Why?
|
| Saliva | 2 | 2012 | 115 | 0.370 |
Why?
|
| MicroRNAs | 7 | 2019 | 501 | 0.370 |
Why?
|
| Extracellular Matrix | 1 | 2012 | 129 | 0.360 |
Why?
|
| Epithelium, Corneal | 2 | 2009 | 10 | 0.350 |
Why?
|
| Glucose | 1 | 2012 | 242 | 0.340 |
Why?
|
| Corneal Stroma | 2 | 2008 | 6 | 0.340 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 137 | 0.310 |
Why?
|
| Peptides | 1 | 2012 | 357 | 0.310 |
Why?
|
| Thymidine Kinase | 1 | 2009 | 9 | 0.300 |
Why?
|
| Cornea | 7 | 2013 | 81 | 0.290 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1420 | 0.240 |
Why?
|
| Epinephrine | 3 | 2003 | 37 | 0.230 |
Why?
|
| Butyrates | 3 | 2011 | 34 | 0.220 |
Why?
|
| Acyclovir | 3 | 2010 | 7 | 0.220 |
Why?
|
| Blotting, Western | 2 | 2016 | 884 | 0.210 |
Why?
|
| Tears | 4 | 2012 | 11 | 0.210 |
Why?
|
| Simplexvirus | 1 | 2003 | 11 | 0.200 |
Why?
|
| Sequence Deletion | 1 | 2003 | 92 | 0.200 |
Why?
|
| Exons | 1 | 2003 | 91 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2011 | 649 | 0.190 |
Why?
|
| Mice, Inbred BALB C | 5 | 2019 | 686 | 0.190 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 979 | 0.190 |
Why?
|
| Calcium-Binding Proteins | 2 | 2019 | 80 | 0.180 |
Why?
|
| Trifluridine | 3 | 2011 | 3 | 0.170 |
Why?
|
| Neovascularization, Physiologic | 2 | 2019 | 80 | 0.170 |
Why?
|
| Fluorescein Angiography | 2 | 2018 | 8 | 0.160 |
Why?
|
| Ophthalmic Solutions | 2 | 2011 | 18 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 180 | 0.160 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2019 | 20 | 0.150 |
Why?
|
| Viral Load | 2 | 2012 | 344 | 0.150 |
Why?
|
| Genetic Loci | 1 | 2019 | 102 | 0.140 |
Why?
|
| Choroid | 1 | 2018 | 10 | 0.140 |
Why?
|
| Gene Expression Regulation, Viral | 4 | 2011 | 115 | 0.130 |
Why?
|
| Hot Temperature | 2 | 2016 | 141 | 0.130 |
Why?
|
| Valine | 2 | 2010 | 29 | 0.130 |
Why?
|
| Leukostasis | 1 | 2016 | 4 | 0.130 |
Why?
|
| Blood-Retinal Barrier | 1 | 2016 | 11 | 0.130 |
Why?
|
| Fundus Oculi | 1 | 2016 | 7 | 0.130 |
Why?
|
| Retinal Vessels | 1 | 2016 | 29 | 0.120 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 1066 | 0.120 |
Why?
|
| Capillary Permeability | 1 | 2016 | 36 | 0.120 |
Why?
|
| Administration, Topical | 1 | 2016 | 37 | 0.120 |
Why?
|
| Formaldehyde | 1 | 2016 | 30 | 0.120 |
Why?
|
| Acetic Acid | 1 | 2016 | 19 | 0.120 |
Why?
|
| Protease Inhibitors | 1 | 2016 | 53 | 0.120 |
Why?
|
| Naloxone | 1 | 2016 | 56 | 0.120 |
Why?
|
| Receptors, Opioid | 1 | 2016 | 40 | 0.120 |
Why?
|
| Genes, Viral | 2 | 2008 | 64 | 0.120 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2018 | 303 | 0.120 |
Why?
|
| Narcotic Antagonists | 1 | 2016 | 78 | 0.120 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 78 | 0.120 |
Why?
|
| Phytotherapy | 1 | 2016 | 78 | 0.120 |
Why?
|
| Plant Leaves | 1 | 2016 | 134 | 0.120 |
Why?
|
| Female | 11 | 2019 | 23980 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1111 | 0.110 |
Why?
|
| Glutamic Acid | 1 | 2016 | 131 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2016 | 386 | 0.110 |
Why?
|
| Male | 5 | 2016 | 22745 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 310 | 0.100 |
Why?
|
| Betaine | 1 | 2013 | 8 | 0.100 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2013 | 36 | 0.100 |
Why?
|
| Eye Infections, Viral | 1 | 2012 | 4 | 0.100 |
Why?
|
| Dexamethasone | 2 | 2011 | 55 | 0.100 |
Why?
|
| Down-Regulation | 3 | 2010 | 452 | 0.090 |
Why?
|
| Cell Movement | 2 | 2019 | 640 | 0.090 |
Why?
|
| Ganciclovir | 1 | 2011 | 4 | 0.090 |
Why?
|
| Conjunctivitis, Viral | 1 | 2011 | 1 | 0.090 |
Why?
|
| Povidone-Iodine | 1 | 2011 | 2 | 0.090 |
Why?
|
| Adenoviridae Infections | 1 | 2011 | 5 | 0.090 |
Why?
|
| Umbilical Veins | 1 | 2011 | 18 | 0.090 |
Why?
|
| Disease Reservoirs | 1 | 2011 | 24 | 0.090 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2011 | 14 | 0.090 |
Why?
|
| Humans | 13 | 2019 | 42113 | 0.090 |
Why?
|
| Dipeptides | 1 | 2011 | 31 | 0.080 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 50 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 90 | 0.080 |
Why?
|
| Mice, Knockout | 2 | 2018 | 1010 | 0.080 |
Why?
|
| Genes, MHC Class II | 1 | 2009 | 20 | 0.070 |
Why?
|
| RNA, Viral | 1 | 2010 | 317 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 261 | 0.070 |
Why?
|
| Recurrence | 4 | 2012 | 149 | 0.070 |
Why?
|
| Acute Disease | 1 | 2009 | 156 | 0.070 |
Why?
|
| Corneal Opacity | 1 | 2008 | 1 | 0.070 |
Why?
|
| Corneal Neovascularization | 1 | 2008 | 6 | 0.070 |
Why?
|
| Virulence | 2 | 2006 | 238 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2011 | 1582 | 0.070 |
Why?
|
| Eye Proteins | 1 | 2008 | 63 | 0.070 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2007 | 44 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 221 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 727 | 0.070 |
Why?
|
| Gene Expression | 2 | 2008 | 692 | 0.070 |
Why?
|
| Mutation | 2 | 2009 | 1169 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 658 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2006 | 118 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 353 | 0.060 |
Why?
|
| Genotype | 1 | 2008 | 792 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 457 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 454 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 599 | 0.060 |
Why?
|
| Viral Proteins | 2 | 2003 | 196 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 683 | 0.050 |
Why?
|
| Cytokines | 1 | 2008 | 661 | 0.050 |
Why?
|
| Virus Replication | 1 | 2006 | 318 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1265 | 0.050 |
Why?
|
| Chimera | 1 | 2003 | 18 | 0.050 |
Why?
|
| Herpesvirus 2, Human | 1 | 2003 | 9 | 0.050 |
Why?
|
| Up-Regulation | 3 | 2011 | 534 | 0.050 |
Why?
|
| Prodrugs | 1 | 2003 | 31 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2003 | 62 | 0.050 |
Why?
|
| Herpesvirus 5, Bovine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2002 | 68 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 534 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2018 | 1617 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2002 | 201 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2019 | 30 | 0.040 |
Why?
|
| Histones | 2 | 2011 | 194 | 0.030 |
Why?
|
| Species Specificity | 2 | 2012 | 279 | 0.030 |
Why?
|
| Plasmids | 1 | 2018 | 247 | 0.030 |
Why?
|
| Neurons | 1 | 2003 | 1246 | 0.030 |
Why?
|
| Models, Biological | 1 | 2019 | 710 | 0.030 |
Why?
|
| Proteins | 1 | 2018 | 383 | 0.030 |
Why?
|
| Iontophoresis | 2 | 2003 | 10 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 2011 | 7 | 0.020 |
Why?
|
| Tobramycin | 1 | 2011 | 3 | 0.020 |
Why?
|
| Conjunctiva | 1 | 2011 | 6 | 0.020 |
Why?
|
| Macaca | 1 | 2011 | 36 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2011 | 31 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2011 | 37 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2011 | 62 | 0.020 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cytosine | 1 | 2011 | 33 | 0.020 |
Why?
|
| Vero Cells | 1 | 2011 | 109 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2010 | 105 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 189 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 233 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 75 | 0.020 |
Why?
|
| Neuroglia | 1 | 2010 | 131 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2011 | 93 | 0.020 |
Why?
|
| Chemokine CCL8 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2007 | 74 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2009 | 170 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2007 | 44 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 487 | 0.020 |
Why?
|
| Sodium | 1 | 2007 | 101 | 0.020 |
Why?
|
| Macular Degeneration | 1 | 2006 | 30 | 0.020 |
Why?
|
| Chromatin | 1 | 2007 | 179 | 0.020 |
Why?
|
| Androgens | 1 | 2006 | 107 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 351 | 0.010 |
Why?
|
| Estrogens | 1 | 2006 | 202 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 1135 | 0.010 |
Why?
|
| Sex Factors | 1 | 2008 | 1004 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 733 | 0.010 |
Why?
|
| Aqueous Humor | 1 | 2003 | 18 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2003 | 26 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 37 | 0.010 |
Why?
|
| Injections | 1 | 2003 | 40 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2003 | 93 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2003 | 58 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2003 | 122 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 65 | 0.010 |
Why?
|
| Biological Availability | 1 | 2003 | 115 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2003 | 94 | 0.010 |
Why?
|
| Encephalitis, Viral | 1 | 2002 | 6 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 207 | 0.010 |
Why?
|
| Meningoencephalitis | 1 | 2002 | 14 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 2002 | 18 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 314 | 0.010 |
Why?
|
| Olfactory Bulb | 1 | 2002 | 50 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 505 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 508 | 0.010 |
Why?
|
| Phenotype | 1 | 2003 | 774 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 997 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 1188 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 1416 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 1559 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 971 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 3933 | 0.010 |
Why?
|
| Aged | 1 | 2008 | 7958 | 0.010 |
Why?
|
| Rats | 1 | 2003 | 3701 | 0.010 |
Why?
|
| Middle Aged | 1 | 2008 | 11790 | 0.010 |
Why?
|